Quick Facts

Insulet Loss Narrows; Details Weak Revenue Guidance - Quick Facts

Medical devices company Insulet Corp. (PODD) Wednesday reported fourth-quarter net loss of $10 million or $0.21 per share, compared with net loss of $14 million or $0.30 per share last year.

Revenues for the quarter were up 23% at $57.8 million, compared with $47 million a year ago.

Growth was due to enhanced customer base for the company's OmniPod Insulin Management System.

Analysts polled by Thomson Reuters estimated a loss of $0.22 per share on revenues of $59.02 million for the quarter. Analysts' estimates typically exclude special items.

Looking ahead to the first quarter, the company expects revenues of $56 million to $59 million, while analysts currently expect $60.48 million.

For fiscal year 2013, the company estimates revenues of $240 million to $255 million, while analysts currently estimate $262.92 million.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

More Quick Facts